For healthcare professionals and partners
Tested in randomised trials
Enbioma’s dietary recommendations have been studied in randomised clinical trials, including a multicentre trial against the low-FODMAP diet with 12 months of published follow-up.
62.5%
Personalised diet
34.5%
Low-FODMAP diet
12-month follow-up of the low-FODMAP trial. Each dot is one participant assessed at 12 months (69 in total). The six-week primary endpoint did not differ between groups; the authors describe the 12-month findings as hypothesis-generating. Gut Microbes, 2026.
Four publications
Primary endpoint first. Each card gives the design, the numbers and the journal.

Published 2024
Compared with the low-FODMAP diet
Multicentre randomised controlled trial in adults with irritable bowel syndrome: 149 randomised, 121 analysed at six weeks. Both groups improved; the change in IBS-SSS at six weeks, the primary endpoint, did not differ between the personalised diet and low-FODMAP groups.

Published 2026
12-month follow-up
At 12 months, 62.5% of the personalised diet group (25/40) and 34.5% of the low-FODMAP group (10/29) met the responder threshold of a 50-point or greater reduction in IBS-SSS (p = 0.029). Open-label, outcome-assessor blinded; 69 participants assessed at 12 months. The authors describe these findings as hypothesis-generating.

Published 2022
Functional constipation
Single-centre randomised controlled trial: 50 randomised, 45 analysed, six weeks. Three or more complete bowel movements a week at week six: 21 of 25 (84%) in the personalised diet group and 8 of 20 (40%) in the control group, which received sodium picosulfate and conventional care (p = 0.003).

Published 2025
Gut wellness score
A deep-learning score developed on 4,015 gut microbiome profiles and tested on 785 external samples from seven public studies. AUC 93.4% in the paper’s cross-validation, benchmarked against GMWI2, an academic reference index. A retrospective modelling study, not a clinical outcome study or a diagnostic tool.

Inside the trials
- 149randomised in the multicentre trial against the low-FODMAP dietAJG 2024
- 69participants assessed at 12 monthsGut Microbes 2026
- 50randomised in the functional constipation trialJ Clin Med 2022
How to read it
Primary endpoint first
In the low-FODMAP trial, the six-week primary endpoint did not differ between groups. The 12-month responder result comes from the follow-up of the same trial, with fewer participants, and the authors call it hypothesis-generating.
Active comparators
The comparators were the low-FODMAP diet and, in the constipation trial, conventional care with sodium picosulfate. Results describe the personalised diet next to these approaches, not next to no intervention.
What was tested
The trials tested the personalised dietary recommendations. They did not test the supplement suggestions or the report as a whole. The gut wellness score comes from a modelling study, not a clinical trial.
Who took part
Adults with irritable bowel syndrome or functional constipation at hospital centres in Türkiye. The results may not apply to other groups.
What these studies cannot tell you
Open-label designs
Participants knew which diet they followed; outcome assessors were blinded where stated.
Small samples
69 of the 149 randomised participants were assessed at 12 months.
Single centre
The constipation trial ran at one centre and was registered retrospectively.
Company involvement
The studies were sponsored, funded or co-authored by the company, and they have not yet been independently replicated.
Sequencing method
The clinical studies used 16S rRNA sequencing. Reports from shotgun data have not been studied in a clinical trial.
Modelling, not outcomes
The wellness score paper is retrospective and does not test the score for individual follow-up.
Publications
- 01
Tunali V, et al. A multicenter randomized controlled trial of microbiome-based artificial intelligence-assisted personalized diet vs low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet: a novel approach for the management of irritable bowel syndrome. The American Journal of Gastroenterology, 2024; 119(9): 1901-1912. doi:10.14309/ajg.0000000000002862

- 02
Tunali V, et al. Long-term microbiome and clinical effects of a microbiome-guided personalized diet versus low-FODMAP diet in irritable bowel syndrome: a 12-month follow-up randomized controlled trial. Gut Microbes, 2026; 18(1): 2719125. doi:10.1080/19490976.2026.2719125

- 03
Arslan NÇ, et al. Efficacy of AI-assisted personalized microbiome modulation by diet in functional constipation: a randomized controlled trial. Journal of Clinical Medicine, 2022; 11(22): 6612. doi:10.3390/jcm11226612

- 04
Nalbantoğlu ÖU, Ermiş BH, Gündoğdu A. Deep learning-enhanced wellness scores: a population level study on gut microbiome profiling and health prediction. Biomedical Signal Processing and Control, 2025; 110: 108146. doi:10.1016/j.bspc.2025.108146

Enbioma is the only company in this landscape with published 12-month randomized follow-up.
The studies above were sponsored, funded or co-authored by Enbiosis, which develops and operates Enbioma. Company relationships are disclosed in each publication.